FDA approves new treatment for hospital-acquired, ventilator-associated bacterial pneumonia

FDA approves new treatment for hospital-acquired, ventilator-associated bacterial pneumonia

Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration yesterday approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.  The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections.

“A key global challenge we face as a public health agency is addressing the threat of antimicrobial-resistant infections,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D.

Continue reading FDA approves new treatment for hospital-acquired, ventilator-associated bacterial pneumonia at STL.News.